Charles River Laboratories International (CRL) Stock Price, News & Analysis

Company Overview

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Key Stats

• Today's Range: $164.92 to $168.55
• 50-Day Range: $163.77 to $201.76
• 52-Week Range: $160.85 to $275.00
• Volume: 875,390 shs
• Average Volume: 1.02 million shs
• Market Capitalization: $8.49 billion
• P/E Ratio: 20.77
• Dividend Yield: N/A
• Price Target: $204.38
• Consensus Rating: Reduce

Charles River Laboratories International Stock Analysis - MarketRank™

Charles River Laboratories International scored higher than 92% of companies evaluated by MarketBeat, and ranked 82nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Charles River Laboratories International has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on 1 buy rating, 12 hold ratings, and 3 sell ratings.

Amount of Analyst Coverage

Charles River Laboratories International has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 1.87%

Earnings Growth

Earnings for Charles River Laboratories International are expected to grow by 1.87% in the coming year, from $10.18 to $10.37 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Charles River Laboratories International is 20.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of Charles River Laboratories International is 20.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.03.

Price to Earnings Growth Ratio

Charles River Laboratories International has a PEG Ratio of 5.94. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Charles River Laboratories International has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.42% of the outstanding shares of Charles River Laboratories International have been sold short.

Short Interest Ratio / Days to Cover

Charles River Laboratories International has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Charles River Laboratories International has recently increased by 5.61%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Charles River Laboratories International does not currently pay a dividend.

Dividend Growth

Charles River Laboratories International does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.55

Percentage of Shares Shorted

4.42% of the outstanding shares of Charles River Laboratories International have been sold short.

Short Interest Ratio / Days to Cover

Charles River Laboratories International has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Charles River Laboratories International has recently increased by 5.61%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.05

News Sentiment

Charles River Laboratories International has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Charles River Laboratories International this week, compared to 8 articles on an average week.

Search Interest

7 people have searched for CRL on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

3 people have added Charles River Laboratories International to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Charles River Laboratories International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,430,931.00 in company stock.

Percentage Held by Insiders

Only 1.30% of the stock of Charles River Laboratories International is held by insiders.

Percentage Held by Institutions

98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRL Stock Analysis - Frequently Asked Questions

How have CRL shares performed this year?

Charles River Laboratories International's stock was trading at $184.60 at the beginning of the year. Since then, CRL shares have decreased by 10.1% and is now trading at $165.9710.
View the best growth stocks for 2025 here.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) announced its quarterly earnings data on Wednesday, November, 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. The company's revenue was down 1.6% on a year-over-year basis.
Read the conference call transcript.

Is Charles River Laboratories International buying back stock?

Charles River Laboratories International's Board of Directors initiated a stock buyback program on Wednesday, August 7th 2024, which allows the company to buy back $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 9.6% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's board believes its stock is undervalued.

Does Charles River Laboratories International have any subsidiaries?

The following companies are subsidiaries of Charles River Laboratories International: Vigene Biosciences Inc., Retrogenix Limited, Cognate BioServices, HemaCare, CiToxLAB, MPI Research, KWS BioTest, and others.

Who are Charles River Laboratories International's major shareholders?

Charles River Laboratories International's top institutional investors include Riverbridge Partners LLC (0.47%), Boston Trust Walden Corp (0.40%), Mountain Pacific Investment Advisers LLC (0.27%) and Norris Perne & French LLP MI (0.25%). Insiders that own company stock include James C Foster, Birgit Girshick, Joseph W Laplume, William D Barbo, Victoria L Creamer, Richard F Wallman, Michael Gunnar Knell, George Massaro and Shannon M Parisotto.
View institutional ownership trends.

How do I buy shares of Charles River Laboratories International?

Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Charles River Laboratories International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Charles River Laboratories International investors own include NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Home Depot (HD) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 1/27/2025
• Next Earnings (Estimated): 2/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Commercial physical research
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:CRL
• CUSIP: 15986410
• CIK: 1100682
• Web: www.criver.com
• Phone: (781) 222-6000
• Fax: 978-988-5665
• Employees: 21,800
• Year Founded: 1947

Price Target and Rating

• Average Stock Price Target: $204.38
• High Stock Price Target: $290.00
• Low Stock Price Target: $151.00
• Potential Upside/Downside: +23.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.88
• Research Coverage: 16 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $7.99
• Trailing P/E Ratio: 20.77
• Forward P/E Ratio: 16.30
• P/E Growth: 5.94
• Net Income: $474.62 million
• Net Margins: 10.44%
• Pretax Margin: 12.77%
• Return on Equity: 14.29%
• Return on Assets: 6.53%

Debt

• Debt-to-Equity Ratio: 0.61
• Current Ratio: 1.48
• Quick Ratio: 1.14

Sales & Book Value

• Annual Sales: $4.13 billion
• Price / Sales: 2.06
• Cash Flow: $16.58 per share
• Price / Cash Flow: 10.01
• Book Value: $70.15 per share
• Price / Book: 2.37

Miscellaneous

• Outstanding Shares: 51,140,000
• Free Float: 50,471,000
• Market Cap: $8.49 billion
• Optionable: Optionable
• Beta: 1.38